Dosing Regimen Of Anti-Alpha4Beta7-Antibodies

Patent No. EP3329965 (titled "Dosing Regimen Of Anti-Alpha4Beta7-Antibodies") was filed by Millennium Pharmaceuticals on May 2, 2012. The application was issued on Mar 19, 2025.

Patent Summary

A stable formulation of anti-α4β7 antibodies for therapeutic applications in inflammatory bowel disease, comprising a buffer, stabilizer, and antibody. The formulation achieves enhanced stability through a specific molar ratio of non-reducing sugar to antibody, with a buffer component maintaining optimal pH and buffer capacity. The formulation can be formulated as a dry, lyophilized product or liquid solution, with the molar ratio of non-reducing sugar to antibody exceeding 600:1. The formulation maintains the antibody's conformational integrity while protecting its functional groups from degradation, enabling effective therapeutic delivery.

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3329965

MILLENNIUM PHARMACEUTICALS
Application Number
EP18150968A
Filing Date
May 2, 2012
Status
Granted And Under Opposition
Feb 14, 2025
Publication Date
Mar 19, 2025